For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
Search Posts
Letters
Coalition Letter to End IRA Prescription Drug Price Controls
October 31, 2023 Dear Members of Congress, When the Inflation Reduction Act was passed and signed into law a year ago, the…
Blog
This week in ridiculous regulations: Blood donations to mortality tables
Poland voted its nationalist-populist government out of power. The US House of Representatives remained without a speaker, but with a lot of drama. Agencies…
City Journal
Equity vs. Evidence
The U.S. Preventive Services Task Force—a volunteer panel of national experts in prevention and evidence-based medicine that makes recommendations for clinical preventive services such…
National Review
Restricting Pharmacy Benefit Managers Could Decrease Competition and Increase Drug Costs
Congress is considering multiple bills that aim to restrict the ability of pharmacy benefit managers (PBMs) to negotiate discounts and rebates and to require the…
PCMA
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
PCMA cites CEI’s Joel Zinberg anti PBM legislation: “This policy would significantly change drug pricing and utilization and shift billions of dollars annually…
Wall Street Journal
Court to FDA: Stop Playing Doctor
The Food and Drug Administration regulates pharmaceuticals, but it has no business playing doctor and giving you medical advice. That’s the message of a…